The estimated Net Worth of Venture Capital V, L.P.Vers... is at least $6.42 Milhão dollars as of 24 April 2018. Venture Vers owns over 22,841 units of CRISPR Therapeutics AG stock worth over $5,254,909 and over the last 7 years Venture sold CRSP stock worth over $1,164,663.
Venture has made over 1 trades of the CRISPR Therapeutics AG stock since 2018, according to the Form 4 filled with the SEC. Most recently Venture sold 22,841 units of CRSP stock worth $1,164,663 on 24 April 2018.
The largest trade Venture's ever made was selling 22,841 units of CRISPR Therapeutics AG stock on 24 April 2018 worth over $1,164,663. On average, Venture trades about 22,841 units every 0 days since 2018. As of 24 April 2018 Venture still owns at least 115,645 units of CRISPR Therapeutics AG stock.
You can see the complete history of Venture Vers stock trades at the bottom of the page.
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani, eCorp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include: